BioVision Lilly Award to honour scientists from developing countries
Prize will reward research into infectious diseases
The prize will reward three young scientists living and working in a developing country, who have a track record of excellent research in infectious diseases, preferably with an emphasis on tuberculosis, and promise to have a positive impact in the developing world.
Candidates should be under 40 and hold at least a PhD.
Three winners will be selected and invited to attend BioVision 2011 in Lyon, France from 27-29 March.
The winner will receive US$5,000 and the runner-up $2,000, to be used for his or her research. The third prizewinner will receive an invitation to attend BioVision 2011, with travel and hotel costs paid.
The awards will be presented at a ceremony hosted by BioVision, TWAS and Lilly, during the exhibition.
The closing date for nominations is 15 January 2011.
You may also like
Research & Development
€2.5m boost for SensABLATE to revolutionise real-time lung cancer treatment
The next-generation AI and photonics system is designed to provide instant intraoperative confirmation during lung cancer ablation and aims to improve precision, reduce repeat procedures and enhance patient outcomes
Regulatory
FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment
The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Research & Development
Vivan Therapeutics and MRC LMS launch partnership to study how KRAS mutations, diabetes and diet shape cancer drug response
The new collaboration will investigate how KRAS mutations and metabolic conditions such as diabetes influence chemotherapy effectiveness, using high-throughput in vivo “fly avatar” models
Research & Development
Gates Foundation awards Keltic Pharma $1.3 million for malaria drug research
The University of Glasgow spin-out's malaria programme is moving towards IND enablement within the next 12 months and is designed to deliver a single-dose cure — a potential breakthrough in efforts to combat one of the world’s most lethal diseases